Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors (MYTHIC)
進行性固形腫瘍患者におけるRP-6306単独またはRP-3500との併用の安全性、薬物動態、薬力学および予備的臨床活性に関する第1相試験
The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Phase 1/1b, multi-center, open-label, dose-escalation study to:
- Evaluate the safety profile and MTD of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib when administered orally to establish the recommended Phase 2 dose and schedule
- Characterize the PK and pharmacodynamics of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib
- Assess preliminary anti-tumor activity associated with lunresertib alone and in combination with RP-3500 or in combination with zedoresertib
This study was previously posted by Repare Therapeutics. In September 2025, sponsorship of the trial was transferred to Debiopharm International S.A
Expanded Access Status: There is no expanded access program available for the investigational products in this study at this time.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Debiopharm International S.A
- 電話番号:+41 21 321 01 11
- メール:clinicaltrials@debiopharm.com
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90095
- 完了
- # 1019, UCLA, Westwood Cancer Center
-
San Francisco、California、アメリカ、94158
- 募集
- #1025, University of California San Francisco
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06520
- 募集
- #1012, Yale
-
-
Florida
-
Jacksonville、Florida、アメリカ、32224
- 募集
- #1017, Mayo Clinic
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- 募集
- #1002, Dana Farber Cancer Institute
-
-
Michigan
-
Grand Rapids、Michigan、アメリカ、49503
- 募集
- #1023, START Midwest
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55902
- 募集
- #1016, Mayo Clinic
-
-
Missouri
-
St Louis、Missouri、アメリカ、63130
- 募集
- #1011, Washington University
-
-
New York
-
New Hyde Park、New York、アメリカ、11042
- 募集
- #1032, Northwell Health Cancer Institute
-
New York、New York、アメリカ、10065
- 募集
- #1004, Memorial Sloan Kettering Cancer Institute
-
New York、New York、アメリカ、10032
- 完了
- #1008, Columbia University
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- 完了
- #1010, University of Pennsylvania
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02903
- 募集
- #1007, Rhode Island Hospital
-
Providence、Rhode Island、アメリカ、02903
- 募集
- #1030, Women & Infants Hospital of Rhode Island
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- #1001, The University of Texas M.D. Anderson Cancer Center
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- 募集
- #1013, The University of Utah
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22903
- 募集
- #1027, University of Virginia
-
-
-
-
-
London、イギリス、W1G 6AD
- 募集
- #3003, Sarah Cannon Research Institute
-
-
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 1X8
- 完了
- #2002, The Hospital for Sick Children
-
Toronto、Ontario、カナダ、M5G 2C1
- 募集
- #2001, Princess Margaret Cancer Centre
-
-
Quebec
-
Montreal、Quebec、カナダ、H4A 3J1
- 完了
- #2003, The Research Institute of the McGill University Health Centre
-
-
-
-
-
Madrid、スペイン、28027
- まだ募集していません
- Clinica Universidad de Navarra
-
Madrid、スペイン、28050
- 募集
- Hospital Universitario HM Sanchinarro
-
Madrid、スペイン、28040
- 募集
- START Madrid. Hospital Fundación Jimenez Diaz
-
Navarra、スペイン、31008
- まだ募集していません
- Clinica Universidad de Navarra
-
-
-
-
-
Copenhagen、デンマーク
- 募集
- #4001, Rigshospitalet - Blegdamsvej
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male or female and ≥12 years-of-age at the time of informed consent.
- Lansky performance status ≥50% for patients ≤16 years of age, or ECOG score of 0, 1, (or 2 for module 1) for patients >16 years of age.
- Locally advanced or metastatic resistant or refractory solid tumors.
- Patients <18 years of age must weigh at least 40 kg.
- Submission of available tumor tissue at screening or willingness to have a biopsy performed if safe and feasible
- Next generation sequencing (NGS) report obtained in a CLIA-certified or equivalent laboratory demonstrating eligible tumor biomarker.
- CCNE1 amplification (non-equivocal) as determined by either a tumor or plasma NGS test, or FISH
- FBXW7 deleterious mutations identified by either a tumor or plasma NGS test
- PPP2R1A deleterious mutations identified by either a tumor or plasma NGS test
- Measurable disease as per RECIST v1.1. For certain modules, patients with prostate cancer or ovarian cancer that have non-measurable disease but have elevated tumor markers (PSA or CA-125, respectively) can also be eligible
- Ability to swallow and retain oral medications.
- Acceptable hematologic and organ function at screening.
- Negative pregnancy test (serum) for women of childbearing potential (WOCBP) at Screening.
- Resolution of all toxicities of prior therapy or surgical procedures.
- Any prior radiation must have been completed at least 7 days prior to the start of study drugs, and patients must have recovered from any acute adverse effects prior to the start of study treatment.
Exclusion Criteria:
- Chemotherapy or small molecule antineoplastic agent given within 21 days or <5 half-lives, whichever is shorter, prior to first dose of study drug.
- History or current condition, therapy, or laboratory abnormality that might confound the study results or interfere with the patient's participation for the full duration of the study treatment.
- Patients who are pregnant or breastfeeding.
- Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction or other reasons which, in the investigator's opinion, could compromise the participating patient's safety.
- Major surgery within 4 weeks prior to first dose of lunresertib.
- Uncontrolled, symptomatic brain metastases.
- Uncontrolled hypertension.
- Certain prior anti-cancer therapy
- Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Phase 1: Lunresertib Single-Agent, Dose Escalation and Food-effect Study
Patients receive lunresertib orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified. |
Oral PKMYT1 Inhibitor |
|
実験的:Phase 1: Lunresertib in combination with RP-3500, Dose Escalation Study
Patients receive lunresertib with RP-3500 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified. |
Oral PKMYT1 Inhibitor Oral ATR Inhibitor |
|
実験的:Phase 1: Lunresertib in combination with Zedoresertib, Dose Escalation Study
Patients receive lunresertib with zedoresertib orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified. |
Oral PKMYT1 Inhibitor Oral WEE1 Inhibitor
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety and Tolerability of lunresertib either in monotherapy or in combination with RP-3500 or with Zedoresertib in patients with eligible advanced solid tumors
時間枠:Up to 90 days after last administration of study intervention
|
Assessed by treatment-emergent adverse events (TEAEs), physical examinations (PEs), safety laboratory assessments, electrocardiograms (ECGs), and vital sign measurements |
Up to 90 days after last administration of study intervention
|
|
To define the MTD of lunresertib monotherapy, and determine a recommended Phase 2 dose (RP2D) and preferred schedule
時間枠:Up to 90 days after last administration of study intervention
|
Assessed by the incidence of Dose-limiting toxicities (DLTs) and the incidence and severity of cumulative safety data |
Up to 90 days after last administration of study intervention
|
|
To define the MTD of lunresertib in combination with RP-3500 or in combination with Zedoresertib, and determine a recommended Phase 2 dose (RP2D) and preferred schedule
時間枠:Up to 90 days after last administration of study intervention
|
Assessed by the incidence of dose-limiting toxicities (DLTs) and the incidence and severity of cumulative safety data |
Up to 90 days after last administration of study intervention
|
|
The relative bioavailability of lunresertib capsule formulation as compared to lunresertib tablet formulation in the fasted state
時間枠:Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
|
Assessed by the plasma concentrations of lunresertib with calculation of pharmacokinetic (PK) parameters including maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), area under the plasma concentration-time curve (AUC) , for both formulations in the fasted state. |
Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
|
|
The effect of food on the PK of tablet formulation of lunresertib when administered in fed conditions compared to administration under fasted conditions
時間枠:Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
|
Assessed by the plasma concentrations of lunresertib with calculation of the ratio of PK parameters (e.g., Cmax and AUC) between the tablet formulation under fasted and fed state. |
Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
|
|
To assess the safety and tolerability of lunresertib tablets in combination with RP-3500, confirm the MTD of lunresertib tablets in combination with RP-3500, and determine a RP2D and preferred schedule
時間枠:Up to 90 days after last administration of study intervention
|
Assessed by DLTs, TEAEs, safety laboratory assessments, the incidence of DLTs and the incidence and severity of cumulative safety data |
Up to 90 days after last administration of study intervention
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The plasma concentrations of lunresertib monotherapy (capsule formulation) in the fasted and fed states
時間枠:Up to 90 days after last administration of study intervention
|
Assessed by the plasma concentrations of lunresertib with calculation of maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), minimum observed plasma concentration (Cmin), area under the plasma concentration-time curve (AUC), elimination half-life (t1/2), and other parameters as appropriate |
Up to 90 days after last administration of study intervention
|
|
To assess the relationship between pharmacodynamic biomarkers and PK of lunresertib at different dose levels and/or schedules
時間枠:Up to 90 days after last administration of study intervention
|
Assessed by evaluation of biomarkers in pre- and on-treatment biopsies, and circulating tumor DNA (ctDNA) dynamics during treatment |
Up to 90 days after last administration of study intervention
|
|
The plasma concentrations of lunresertib and RP-3500 when dosed in combination
時間枠:Up to 90 days after last administration of study intervention
|
Assessed by the plasma concentrations of lunresertib and RP-3500 with calculation of maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), minimum observed plasma concentration (Cmin), area under the plasma concentration-time curve (AUC), elimination half-life (t1/2), and other parameters as appropriate for each analyte |
Up to 90 days after last administration of study intervention
|
|
To assess preliminary anti-tumor activity achieved with lunresertib monotherapy, lunresertib in combination with RP-3500 or lunresertib in combination with Zedoresertib
時間枠:Through Study Completion, an average of 1 year
|
Measured by best percent change in tumor size from baseline, objective response rate (ORR), overall response rate, tumor marker response, duration of response (DOR), clinical benefit rate (CBR), progression-free survival (PFS). |
Through Study Completion, an average of 1 year
|
|
To assess the safety and anti-tumor effects of lunresertib capsule + RP-3500
時間枠:Through Study Completion, an average of 1 year
|
As measure by TEAEs, safety laboratory assessments, Best percent change in tumor size from baseline, ORR, overall response rate, DOR, CBR, tumor marker response, PFS |
Through Study Completion, an average of 1 year
|
|
To further characterize the PK of lunresertib tablets and assess preliminary anti-tumor
時間枠:Through Study Completion, an average of 1 year
|
Measured by Plasma concentrations of lunresertib with calculation of Cmax, Tmax, AUC, elimination t1/2, and other PK parameters as appropriate, Best percent change in tumor size from baseline, ORR, overall response rate, DOR, CBR, tumor marker response, PFS |
Through Study Completion, an average of 1 year
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- Debio 0123-106
- RP-6306-01 (その他の識別子:Repare Therapeutics)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。